Several chemotherapeutic agents used in cancer treatment including DOX can induce the release of HMGB1 into the tumor environment after cell death and suggest that neutrophil cells and macrophages will be activated by cytokines as part of the innate immune response against cancer cells and will actively excrete HMGB1. Here, HMGB1 is linked to neoplasm.